Non-invasive molecular imaging of prostate cancer lymph node metastasis

Trends in Molecular Medicine

Volumn 15, Issue 6, 2009, Pages 254-262

  Pouliot, Frédéric ^a   Johnson, Mai ^a   Wu, Lily ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; GENE AMPLIFICATION; HUMAN; LYMPH NODE METASTASIS; MOLECULAR IMAGING; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; REVIEW;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 66549119389     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2009.04.004     Document Type: Review

References (62)

1. + patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur. Urol. (in press)
2. D'Amico A.V., et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J. Clin. Oncol. 21 (2003) 2163-2172
3. Shariat S.F., et al. Inventory of prostate cancer predictive tools. Curr. Opin. Urol. 18 (2008) 279-296
4. Bader P., et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?. J. Urol. 169 (2003) 849-854
5. Daneshmand S., et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J. Urol. 172 (2004) 2252-2255
6. Heesakkers R.A., et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol. 9 (2008) 850-856
7. Grubnic S., et al. MR evaluation of normal retroperitoneal and pelvic lymph nodes. Clin. Radiol. 57 (2002) 193-200
8. Cserni G. Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work up. J. Clin. Pathol. 52 (1999) 922-924
9. Harisinghani M.G., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348 (2003) 2491-2499
10. Burkhard F.C., et al. The role of lymphadenectomy in prostate cancer. Nat. Clin. Pract. Urol. 2 (2005) 336-342
11. Schoder H., et al. Molecular targeting of the lymphovascular system for imaging and therapy. Cancer Metastasis Rev. 25 (2006) 185-201
12. Al-Sarraf N., et al. Mediastinal lymph node staging by means of positron emission tomography is less sensitive in elderly patients with non-small-cell lung cancer. Clin. Lung Cancer 9 (2008) 39-43
13. Birim O., et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann. Thorac. Surg. 79 (2005) 375-382
14. Crippa F., et al. FDG-PET for axillary lymph node staging in primary breast cancer. Eur. J. Nucl. Med. Mol. Imaging 31 Suppl 1 (2004) S97-S102
15. Jereczek-Fossa B.A., et al. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat. Rev. 30 (2004) 153-164
16. Kramer H., and Groen H.J. Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer. Ann. Surg. 238 (2003) 180-188
17. Mueller-Lisse U.G., et al. Functional imaging in penile cancer: PET/computed tomography, MRI, and sentinel lymph node biopsy. Curr. Opin. Urol. 18 (2008) 105-110
18. Prichard R.S., et al. Positron emission tomography for staging and management of malignant melanoma. Br. J. Surg. 89 (2002) 389-396
19. Rice T.W. Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg. Clin. N. Am. 10 (2000) 471-485
20. Strauss L.G. Sensitivity and specificity of positron emission tomography (PET) for the diagnosis of lymph node metastases. Recent Results Cancer Res. 157 (2000) 12-19
21. Vansteenkiste J.F. Imaging in lung cancer: positron emission tomography scan. Eur. Respir. J. Suppl. 35 (2002) 49s-60s
22. Wagner J.D., et al. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J. Surg. Oncol. 77 (2001) 237-242
23. Antoch G., et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. J. Am. Med. Assoc. 290 (2003) 3199-3206
24. Machtens S., et al. Positron emission tomography (PET) in the urooncological evaluation of the small pelvis. World J. Urol. 25 (2007) 341-349
25. Liu I.J., et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57 (2001) 108-111
26. Oyama N., et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn. J. Clin. Oncol. 29 (1999) 623-629
27. Seltzer M.A., et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J. Urol. 162 (1999) 1322-1328
28. Sanz G., et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int. 84 (1999) 1028-1031
29. Sung J., et al. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int. 92 (2003) 24-27
30. Scattoni V., et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur. Urol. 52 (2007) 423-429
31. de Jong I.J., et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J. Nucl. Med. 44 (2003) 331-335
32. Husarik D.B., et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 35 (2008) 253-263
33. Heinisch M., et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?. Mol. Imaging Biol. 8 (2006) 43-48
34. Fricke E., et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 30 (2003) 607-611
35. Oyama N., et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J. Nucl. Med. 44 (2003) 549-555
36. Kotzerke J., et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 29 (2002) 1380-1384
37. Sandblom G., et al. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 67 (2006) 996-1000
38. Albrecht S., et al. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 185-196
39. Morris M.J., and Scher H.I. (11)C-acetate PET imaging in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 181-184
40. Schuster D.M., et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J. Nucl. Med. 48 (2007) 56-63
41. Bouchelouche K., and Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J. Urol. 179 (2008) 34-45
42. Larson S.M., and Schoder H. Advances in positron emission tomography applications for urologic cancers. Curr. Opin. Urol. 18 (2008) 65-70
43. Haseman M.K., et al. Capromab Pendetide imaging of prostate cancer. Cancer Biother. Radiopharm. 15 (2000) 131-140
44. Polascik T.J., et al. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer 85 (1999) 1586-1592
45. Zanzi I., and Stark R. Detection of a non-Hodgkin's lymphoma by capromab pendetide scintigraphy (ProstaScint) in a patient with prostate carcinoma. Urology 60 (2002) 514
46. Chang S.S., et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59 (1999) 3192-3198
47. Pandit-Taskar N., et al. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J. Nucl. Med. 49 (2008) 1066-1074
48. Leyton J.V., et al. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin. Cancer Res. 14 (2008) 7488-7496
49. Burton J.B., et al. Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat. Med. 14 (2008) 882-888
50. Wu L., and Sato M. Integrated, molecular engineering approaches to develop prostate cancer gene therapy. Curr. Gene Ther. 3 (2003) 452-467
51. Wu L., et al. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther. 8 (2001) 1416-1426
52. Adams J.Y., et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat. Med. 8 (2002) 891-897
53. Iyer M., et al. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14595-14600
54. Min J.J., and Gambhir S.S. Molecular imaging of PET reporter gene expression. Handb Exp Pharmacol. 185 (2008) 277-303
55. Serganova I., et al. Human reporter genes: potential use in clinical studies. Nucl. Med. Biol. 34 (2007) 791-807
56. Johnson M., et al. Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach. Mol. Imaging 4 (2005) 463-472
57. Huyn, S. et al. A potent imaging adenoviral vector driven by the cancer selective mucin-1 promoter that targets breast cancer metastasis. Clin. Cancer Res. (in press)
58. Ray S., et al. Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy. Mol. Ther. 16 (2008) 1848-1856
59. Sato M., et al. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin. Cancer Res. 11 (2005) 3743-3749
60. Zhang L., et al. Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res. 63 (2003) 4552-4560
61. Ilagan R., et al. Imaging mitogen-activated protein kinase function in xenograft models of prostate cancer. Cancer Res. 66 (2006) 10778-10785
62. Thompson I., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 177 (2007) 2106-2131